Composés organosiliciés

Stability Air Sensitive, Moisture Sensitive
Applications It is used for synthesis of unsymmetrical biaryls via aromatic C-H borylation-cross-coupling sequence.
References Stephens, T. et al.: Org. Lett., 19, 3498 (2017);

Stability Moisture Sensitive
Applications n-Octadecyltrichlorosilane (cas# 112-04-9) is a useful research chemical.
E0

Applications TRIMETHYL(BROMODIFLUOROMETHYL)SILANE (cas# 115262-01-6) is a useful research chemical.

Stability Moisture Sensitive
Applications Chloroborane Methyl Sulfide Complex is a reagent in the synthesis of 3,4-Dimethyl-5-pentyl-2-furanundecanoic Acid (D477535); a furan fatty acid known to exhibit radical-scavenging ability and having anti-inflammatory properties.
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Grahl, N., et al.: Marine. Biol., 157, 1567 (2010); Spiteller, G., et al.: Lipids., 40, 75 (2005); Wakimoto, T., et al.: PNSA., 108, 17533 (2011)

Applications methyl 4-(bromomethyl)-3-(tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (cas# 1626407-50-8) is a useful research chemical.

Impurity Paclitaxel - In House Impurity
Applications Protected Baccatin III. Paclitaxel - In House Impurity.

Stability Moisture Sensitive
Applications Chlorotriethylsilane is used in the preparation of potent silylating agent and lewis acid catalyst. Chlorotriethylsilane derivatived ethers have been shown to be more stable towards hydrolysis than are trimethyl ethers.
E0
References Alvisi, C. et al.: J. Org. Chem., 63, 1330 (1998): Higashiya, S. et al.: J. Org. Chem., 69, 6326 (2004); Hicks, J.D. et al.: Org. Lett., 9, 5621 (2007);

Applications 4-Acetylphenylboronic acid4-Acetylphenylboronic Acid is used in several metal catalyzed cross-coupling reaction studies.
References Saito, S., et al.: J. Org. Chem., 2, 8024 (1997); Sakai, M., et al.: Organomet., 16, 4229 (1997); Molander, G., et al.: J. Org. Chem., 68, 4302 (2003);

Applications tert-Butyl-(3-iodo-1,1-dimethyl-propoxy)-dimethyl-silane (cas# 105262-85-9) is used as a reagent in the preparation of Methyl Acetoacetate.
References Heslin, J. C., et al.: J. Chem. Soc. [Perkin 1]. 6, 1417 (1988)

Applications 2-(6,6-Dimethyl-1-cyclohexen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane was used in the preparation of conformationally constrained cyclic carboxylic acid derivatives useful as GPR40 modulators for treating metabolic disorders.

Applications 3-(Cyclopropylaminocarbonyl)phenylboronic acid

Applications TETRAMETHYLAMMONIUM BOROHYDRIDE (cas# 16883-45-7) is a useful research chemical.

Applications Trimethylboroxin (50% Solution in THF) is used in a diverse array of areas, including as a polymerization additive. Trimethylboroxin is also used in the preparation of CBS catalysts for asymmetric reductions.
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Gilmore, N., et al.: Tetrahedron Asy., 14, 2115 (2003); Najera, C., et al.: Adv. Synth. Catal., 346, 1798 (2004);

Stability Moisture Sensitive
Applications 1-(Trimethylsiloxy)cyclohexene is used as a reagent in the synthesis of 6-Methyl Chrysene (M265140); an aryl hydrocarbon receptor (AhR) agonist that has been listed as possibly carcinogenic to humans.
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Amin, S. et al.: Cancer Res., 45, 6406 (1985); Blaha, L. et al.: Toxicol. Sci., 65, 43 (2002); Brack, W. et al.: Environ. Sci. Technol., 37, 3062 (2003); Andrysik, Z. et al.: Mutat. Res., 615, 87 (2007)

Applications (2-Ethynylphenyl)boronic acid

Applications 2-tert-Butyldimethylsilyloxyethyl Tosylate is an intermediate in the synthesis of Everolimus (E945400), which is Everolimus Macrolide immunosuppressant; Everolimus is a derivative of Rapamycin. Everolimus inhibits cytokine-mediated lymphocyte proliferation.
References Dumont, F.J., et al.: Curr. Opin. Invest. Drugs, 2, 1220 (2001), Kovarik, J. M., et al.: Clin. Pharmacol. Ther., 69, 48 (2001), Nashan, B., et al.: Ther. Drug Monit., 24, 53 (2002),